Istanbul Sisli Hamidiye Etfal Training and Research Hospital, Center for Blood, University of Health Sciences, Istanbul, Turkey.
Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Medical Microbiology, Istanbul, Turkey.
New Microbiol. 2021 Oct;44(4):217-226. Epub 2021 Dec 19.
We aimed to detect EBV/Hp (Epstein-Barr Virus/Helicobacter pylori) co-infection by determining the number of copies of EBV/EBER-1 in the gastric biopsy samples of the Hp (+) GC, peptic ulcer (PU), and non-ulcer dyspepsia (NUD) cases. The patient group (PG), with 34 patients (34 GC and 30 PU patients) and a control group with 40 NUD cases were included. All patients and controls were Hp positive. EBV/EBNA-1 IgG were measured by the Anti-EBNA-1 ELISA IgG kit. Determination and quantification of EBV/EBER-1 gene region was performed by qPCR. EBV/EBER-1 positivity was 35.29% (12/34), 6.6% (2/30) and 2.5% (1/40) in GC, PU and 40 NUD cases, respectively. A significant difference was found between the GC and NUD cases (p=0.001). A significant difference was found between the groups for mean EBV/EBER-1 copy numbers (p=0.019). No significant difference was found between GC and the NUD cases (p=0.1455) for EBV/EBNA-1 IgG antibody positivity. EBV/EBER-1 positivity (OR=3.319), and age ≥55 years old (OR=2.331) were found to be a significant in multivariate logistic regression. In conclusion, our data suggest that the GC risk by EBVand Hp co-infection increased 3.3 times.
我们旨在通过检测胃活检样本中 EBV/EBER-1 的拷贝数来检测 EBV/Hp(Epstein-Barr 病毒/幽门螺杆菌)共感染。将 34 例 Hp(+)GC、消化性溃疡(PU)和非溃疡性消化不良(NUD)患者(PG)和 40 例 NUD 对照组纳入研究。所有患者和对照组均为 Hp 阳性。采用 Anti-EBNA-1 ELISA IgG 试剂盒检测 EBV/EBNA-1 IgG。通过 qPCR 检测和定量 EBV/EBER-1 基因区域。GC、PU 和 40 例 NUD 患者中 EBV/EBER-1 阳性率分别为 35.29%(12/34)、6.6%(2/30)和 2.5%(1/40)。GC 与 NUD 组之间存在显著差异(p=0.001)。各组之间 EBV/EBER-1 拷贝数的平均值存在显著差异(p=0.019)。GC 与 NUD 组之间 EBV/EBNA-1 IgG 抗体阳性率无显著差异(p=0.1455)。多元逻辑回归分析显示,EBV/EBER-1 阳性(OR=3.319)和年龄≥55 岁(OR=2.331)是显著的。综上所述,我们的数据表明 EBV 和 Hp 共感染使 GC 风险增加了 3.3 倍。